Poliomyelitis vaccination what are the options?

Clinical Immunotherapeutics

Volumn 6, Issue 1, 1996, Pages 1-6

  Melnick, Joseph L ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POLIOMYELITIS VACCINE;

COST BENEFIT ANALYSIS; DOSE RESPONSE; DRUG COST; DRUG DELIVERY SYSTEM; DRUG EFFICACY; GEOGRAPHIC DISTRIBUTION; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; POLIOMYELITIS; PRIORITY JOURNAL; REVIEW; VACCINATION; VIRUS INACTIVATION;

EID: 0029761218     PISSN: 11727039     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03259348     Document Type: Article

References (23)

1. Melnick JL, Ashkena/i A. Midulla VC. et al. Inimunogenic potency of MgCh-stahili/ed oral polio\accine. JAMA 1963: 1X5:406-8
2. Melnick JL, Thermostahility ol'polio\ irus. measles, and hepatitis B vaccines. Vaeeine Res 1995; 4: 1-9
3. Rons; W, Georgescu M. Delpejroux F. el al. Thermostabilizatiun of live virus vaccines by heavy water (D:O|. Vaccine 1995; 13: 1058-63
4. Melnick JL, Live attenuated puliovaccines. In: Plotkin SA. Mortimer EA Jr. editors. Vaccines. 2nd ed. Philadelphia: Saumlers. 1990: 155-204
5. Wright PF, Kim-Farley RJ. de Quadrus CA. et al. Strategies lor the global eradication of poliomyelitis b\ the year 2000. N FngIJ Med 1991:325: 1774-9
6. Melnick JL, Fntenn iruses: polioviruses. coxsackicviruses. echovirnses. and newer enteroviruses. In: Fields BN. Knipe DM. Chanock RM. et al., editors. Field's \irology. 2nd ed. New York: Raven Press. 1990: 549-605
7. Sulk J, Drucker JA. Malvy D. Noninfectiouspoliovirns vaccine. In: Plotkin SA. Mortimer HA Jr. editors. Vaccines. 2nd ed. Philadelphia: Saunders. 1990: 205-27
8. van We/el AL, van Steenis Ci. van der Marel P. et al. Inactivated polimirus vaccine: current production methods and new developments. Re\ Infect Dis 1984: 6 Suppl. 2: S335-40
9. WHO EPI Global Ad\ isory Group, Summary of conclusions and recommendations. Wkly Bpidemiol Rec 1985: 60: 13-6
10. Sabin AB, Perspccti\es on rapid elimination and ultimate global eradication ol paralytic poliomyelitis caused by polio-uruscs. Fur J Epidemiol 1991: 7: 95-120
11. Lemon SM, Robertson SE. Global eradication of poliomyelitis: recent progress, future prospects, and new research priorities. Prog MedVirol 1991: 38:42-55
12. De Quadros CA, Andrus JK. Olhe J-M. et al. Eradication of poliomyelitis: progress in the Americas. Pediatr Infect Dis J 1991; ](): 222-9
13. Jamison DT, Torres AM. Chéri LC. et al. Poliomyelitis: what are the prospects for eradication and rehabilitation'.' Health Policy Plan 1991:6: 107-18
14. Melnick JL, Poliomyelitis: eradication in sight1 Fpidemiol hit 1992: 108: 1-18
15. Sabin AB, Paralytic poliomyelitis: old dogmas and new perspeclhes. Re\ Infect Dis 1981; v 543-64
16. Tulchinsky TH, Handsher R, Melnick JL, et al, Immune status to various strains of wild poliovirus among children in Gaza immunized with live attenuated oral vaccine alone compared with a combination of live and inactivated vaccines. J Viral Dis 1994; 1:5-13
17. Von Magnus H, Petersen 1, Vaccination with inactivated poliovirus vaccine and oral poliovirus vaccine in Denmark. Rev Infect Dis 1984; 6: S47I-4
18. Slater PE, Orenstein WA, Morag A, et al, Poliomyelitis outbreak in Israel in 1988: a report with two commentaries. Lancet 1990:335: 1192-8
19. Lasch E, Abed Y, Abdulla K, et al, Successful results of a program combining live and inactivated poliovirus vaccines to control poliomyelitis in Gaza. Rev Infect Dis 1984; 6: S467-S470
20. Faden H, Modlin JF, Thomas ML, et al, Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated (rivaient poliovirus vaccines in childhood: systemic and local immune responses. J Infect Dis 1990; 162: 1291-7
21. Patriarca PA, Wright PF, John TJ, Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis 1991; 13: 926-39
22. Almond JW, The attenuation of poliovirus neurovirulence. Annu Rev Microbiol 1987; 41: 153-80
23. Correspondence and reprints: Dr Joseph L, Melnick, Division of Molecular Virology, Baylor College of Medicine, One Baylor Plaza, Suite 735, Houston, TX 77030, USA.